Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Masimo (NASDAQ: MASI) announced findings from a study published in Pediatrics International, which evaluated the efficacy of its noninvasive PVi® technology in predicting fluid responsiveness for children aged 1-3 undergoing major neurosurgery. The study indicated that PVi and ∆Vpeak were effective predictors, while traditional pressure-based methods performed poorly. Out of 60 patients, 26 were identified as fluid responders, with baseline PVi showing a diagnostic accuracy AUROC of 0.775. This research highlights PVi's potential to enhance fluid management in pediatric surgery and underscores Masimo's commitment to improving outcomes for vulnerable patients.
Masimo (NASDAQ: MASI) has announced a strategic collaboration with Temple Health, focusing on remote patient monitoring and telehealth advancements. This partnership will explore the integration of Masimo's advanced technologies, including the W1™ health tracking watch and the Radius VSM™ patient monitor, to enhance healthcare delivery. They aim to improve health outcomes while raising awareness of health equity in Philadelphia. Both organizations will leverage their expertise to innovate and conduct joint clinical research. Notably, the W1™ and Radius VSM are awaiting FDA clearance, indicating potential future growth opportunities.
Masimo (NASDAQ: MASI) announced findings from a study published in the British Journal of Neurosurgery indicating that the noninvasive Pleth Variability Index (PVi) is as effective as the invasive stroke volume variation (SVV) for guiding intraoperative fluid management during neurosurgery. Conducted among 60 adult patients undergoing elective craniotomy, the study suggests PVi may be preferable given its noninvasive nature. Although fluid volume administered was higher in the SVV group (3208.3 mL vs. 2139.3 mL), other clinical outcomes like serum lactate and stay duration showed comparable results. CEO Joe Kiani emphasized PVi's cost-effectiveness and low risk.
Politan Capital Management, holding 9% of Masimo (NASDAQ: MASI), announced that the California State Teachers’ Retirement System (CalSTRS) has joined its lawsuit against the Company’s CEO Joe Kiani over his controversial employment agreement. The agreement may grant Mr. Kiani approximately
Masimo (NASDAQ: MASI) announced its participation in the 44th Annual Raymond James Institutional Investors Conference on March 7, 2023, at 11:00 a.m. Eastern Time. Investors can access a live webcast of the presentation on the Masimo website, with a replay available afterward.
Masimo is a leading global medical technology company known for its innovative monitoring solutions, including the Masimo SET®, which has been shown to outperform other pulse oximetry technologies. The company aims to enhance patient outcomes and reduce healthcare costs through its advanced technologies.
Masimo reported strong financial results for Q4 and full-year 2022, with consolidated revenue reaching $617 million and $2,035.8 million respectively. The healthcare revenue was $351.9 million in Q4, growing 7.4% year-over-year, while full-year healthcare revenue hit $1,340.3 million with 8.2% growth. Non-healthcare revenue for Q4 was $265.1 million. The company achieved a GAAP net income of $41.1 million in Q4, or $0.76 per diluted share. For 2023, Masimo projects consolidated revenue between $2,415 million and $2,460 million, indicating continued growth.
Masimo (NASDAQ: MASI) announced findings from a study published in Medicine, showing that using the Oxygen Reserve Index (ORi™) alongside standard SpO2 monitoring effectively reduced intraoperative hyperoxemia during laparoscopic gastrectomy. Conducted by Dr. Jin Hee Ahn and team, the study demonstrated significant differences in arterial oxygen levels; the SpO2 group had a higher PaO2 compared to the ORi-SpO2 group one hour post-surgery (250.31 mmHg vs. 170.07 mmHg, p < .001). The severe hyperoxemia incidence was lower in the ORi-SpO2 group at 16.7% vs. 84.4% for SpO2.
Masimo (NASDAQ: MASI) announced that its Centroid wearable, wireless patient position and activity sensor received an Innovative Technology designation from Vizient, Inc., aimed at improving healthcare practices. Centroid helps prevent hospital-acquired pressure injuries (HAPIs), which affect 2.5 million patients annually in the U.S., with nearly 60,000 fatalities each year. It monitors patient position and movements using Bluetooth technology and integrates with the Masimo Root Patient Monitoring platform.
This recognition positions Masimo for potential growth in healthcare solutions, illustrating its commitment to enhancing patient outcomes and lowering care costs.
Masimo (NASDAQ: MASI) will announce its fourth quarter and FY 2022 financial results on February 28, 2023, after market closure. The results will be reviewed in a conference call at 1:30 p.m. PT (4:30 p.m. ET), hosted by CEO Joe Kiani and CFO Micah Young. Participants must register to obtain the dial-in details. Masimo specializes in medical technology, focusing on noninvasive monitoring solutions to enhance patient outcomes and reduce care costs. Their innovations include pulse oximetry and various blood monitoring technologies, widely used in leading healthcare institutions globally.
Masimo (NASDAQ: MASI) has launched the Visual Clinical Activity Monitoring (VCAM™), an AI-based video analysis system designed to enhance compliance with hand hygiene protocols in hospitals. The VCAM integrates with Masimo Hospital Automation™ solutions, providing real-time notifications and analytics to improve hygiene adherence and reduce hospital-acquired infections (HAIs). A Finnish study indicates a direct correlation between hand hygiene compliance and lower HAI rates. The system tracks handwashing and sanitization activities, offering actionable insights for healthcare facilities.
FAQ
What is the current stock price of Masimo (MASI)?
What is the market cap of Masimo (MASI)?
